Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Bevacizumab/docetaxel

Retrobulbar optic neuritis: case report

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Zhou Y, Zhang Y, Yang X, Fan L, Jiang J.Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer. Breast Journal 18: 502-503, No. 5, Sep 2012. Available from: URL: http://dx.doi.org/10.1111/j.1524-4741.2012.01293.x - China

    Download references

    Additional information

    Key words

    Optic-neuritis; adverse reactions; Bevacizumab; drug-induced; Docetaxel

    An event is serious (FDA MedWatch definition) when the patient outcome is: death; life-threatening; hospitalisation; disability; congenital anomaly; requires intervention to prevent permanent impairment or damage

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Bevacizumab/docetaxel. React. Wkly. 1428, 10 (2012). https://doi.org/10.2165/00128415-201214280-00031

    Download citation

    Keywords

    • Breast Cancer
    • Dexamethasone
    • Visual Acuity
    • Bevacizumab
    • Docetaxel